A Randomized Double Blind Placebo Controlled Study To Evaluate Efficacy And Safety Of Cp-690,550 In Children From 2 To Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (JIA) With Active Systemic Features
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Aug 2017 Planned End Date changed from 20 Oct 2022 to 1 Oct 2022.
- 03 Aug 2017 Planned primary completion date changed from 20 Oct 2022 to 1 Oct 2022.
- 03 Aug 2017 Planned initiation date changed from 4 Aug 2017 to 1 Aug 2017.